Lecanemab-irmb (Leqembi), an anti-amyloid beta (Aβ) protofibril antibody, continues to show benefit for early Alzheimer’s disease (AD) patients over three years, according to new trial results.

Eisai and Biogen shared the latest findings at the Alzheimer’s Association International Conference (AAIC) 2024, held in Philadelphia.

Dual-acting lecanemab is the only early AD treatment widely available to support neuronal function by clearing the highly toxic protofibrils that continue to cause neuronal injury and death even after plaques have been cleared from the brain.

Results from the Clarity AD trial

Clarity AD was a global Phase III placebo-controlled, double-blind, parallel-group, randomised study in 1,795 people with early AD.

The mean change from baseline between the lecanemab treated group and the placebo group was -0.45 on the primary endpoint of the Clinical Dementia Rating-Sum of Boxes (CDR-SB) global cognitive and functional scale.

Over three years of treatment across the core and open-label extension (OLE) studies, lecanemab reduced cognitive decline on the CDR-SB by -0.95 compared to the expected decline based on the Alzheimer’s Disease Neuroimaging Initiative (ADNI) group.

A change from 0.5 to 1 on the CDR score domains of Memory, Community Affairs and Home/Hobbies is the difference between slight impairment and loss of independence, such as people’s ability to be left alone, remember recent events, participate in daily activities, complete household chores, function independently and engage in hobbies and intellectual interests.

After three years of lecanemab treatment, 59% of no tau/low tau patients (24/41) showed improvement or no decline, and 51% (21/41) showed improvement from baseline on the CDR-SB.

On the ADAS-Cog14 measurement scale, 63% of patients showed improvement or no decline and 61% showed improvement. On the ADCS MCI-ADL, 63% of patients showed improvement or no decline and 59% showed improvement.

Lecanemab Phase II trial results

In a Phase IIb trial conducted in 856 patients with early AD, appropriate patients participated in the OLE after an off-treatment period of 9-59 months (mean: 24 months) following the 18-month core study.

During the off-treatment period, lecanemab’s clinical effect was maintained, but the rate of decline reverted back to the rate of decline in patients on placebo. This indicates that even after Aβ plaque is removed, AD continues to progress.

The key AD fluid biomarkers Aβ42/40, pTau181, pTau217, and glial fibrillary acidic protein (GFAP) have been shown to re-accumulate at a faster rate when treatment is discontinued.

Modelling data from the Phase II, Phase III and respective OLE studies showed that the half-life of the treatment effect on the Aβ42/40 ratio, pTau181, and GFAP are lost within 0.5 year, 1.6 years and 1.7 years, respectively. The half-life of the treatment effect on amyloid plaque is gradually lost in 12.1 years.

When lecanemab treatment was resumed after the off-treatment period, Aβ42/40 ratio, pTau181, pTau217 and GFAP improved. This suggests that AD continues to progress when treatment is stopped, even after plaque has been cleared.

The role of protofibrils

Lecanemab is designed to selectively target highly toxic protofibrils in addition to amyloid plaques. Protofibrils accumulate early in the AD brain and lead to nerve cell function loss, abnormal nerve processes, inflammation, and memory loss.

In non-clinical studies, antibodies against protofibrils prevented protofibril-mediated neuronal dysfunction and memory loss. Lecanemab preferentially binds to toxic protofibrils with the highest affinity. After rapidly clearing plaque and existing protofibrils, lecanemab continuously clears the protofibrils that continue to develop and damage neurons.

Protofibrils also play a role in tau spread. In the tau PET substudy, continuous lecanemab treatment slowed the rate of increase in tau accumulation and increase in CSF MTBR-tau243. Additionally, lecanemab improved pTau217 and other biomarkers related to neuroinflammation and neurodegeneration.

Safety concerns with lecanemab

The companies reported no new safety findings with continued lecanemab treatment over three years. Most amyloid-related imaging abnormalities (ARIA) occurred in the first six months of treatment. After the first six months, ARIA rates are low and similar to ARIA rates on placebo. Most patients who had ARIA had CDR-SB assessments after the event. Sensitivity analyses showed ARIA had no impact on cognition or function. From these results ARIA was not associated with accelerated long-term progression.

In its July meeting, the EU Committee for Medicinal Products for Human Use (CHMP) recommended not granting a marketing authorisation for Leqembi (lecanemab) for the treatment of Alzheimer’s disease due to these side-effects.

The committee said that the observed effect of Leqembi on delaying cognitive decline does not counterbalance the risk of serious side events associated with the medicine, in particular the frequent occurrence of ARIA.

Diana Spencer, Senior Digital Content Editor, DDW